Excellergy

About Excellergy

Excellergy is a biotech company pioneering a new class of allergy therapeutics called Trifunctional Effector Cell Response Inhibitors (ECRIs). Their mission is to end allergic suffering by disabling the IgE axis, offering rapid and complete control of allergic responses through innovative treatments that surpass existing therapies.

Products & Services

Trifunctional Effector Cell Response Inhibitors (ECRIs):A new therapeutic class for severe allergic diseases, using a trifunctional mechanism to remove bound IgE from effector cells, neutralize free IgE, and downregulate receptor expression for long-term allergic control.

Exl-111:A lead anti-IgE therapeutic candidate within the ECRI portfolio, designed to rapidly desensitize allergic patients by targeting IgE interactions.

Specialties

Allergy Therapeutics IgE Biology Translational Immunology Effector Cell Response Inhibition Structural Biology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 70000000 MR: - FA: $70 million FAN: 70000000	D: 2025-10-13 FD: 2025-10-13	3 investors

Series A Latest

2025-10-13

$70.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Alexander Eggel

Associate Professor and Scientific Co-Founder

T

Ted Jardetzky

Professor and Chair of Structural Biology

L

Luke Pennington

Vice President, Discovery & Co-Founder

G

Geoff Harris

Chief Scientific Officer & Co-Founder

T

Todd Zavodnick

Chief Executive Officer

P

Phil Brown

Chief Medical Officer

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

Excellergy Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised